← FDA DRUG APPROVALS
FDA ANDA · ANDA202001
PIOGLITAZONE HCL AND METFORMIN HCL
Sponsor: TORRENT PHARMS LTD
APPLICATION
ANDA202001
TYPE
ANDA
ORIGINAL APPROVAL
2013-02-13
LATEST ACTION
2020-02-21
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription
Products
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDEPrescription
METFORMIN HYDROCHLORIDE 850MG, PIOGLITAZONE HYDROCHLORIDE EQ 15MG BASE · TABLET · ORAL
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDEPrescription
METFORMIN HYDROCHLORIDE 500MG, PIOGLITAZONE HYDROCHLORIDE EQ 15MG BASE · TABLET · ORAL
Approval history
2020-02-21Labeling · Supplement 10 · standardAP
2020-02-21Labeling · Supplement 11 · standardAP
2015-09-18Labeling · Supplement 4 · standardAP
2015-09-18Labeling · Supplement 5 · standardAP
2013-02-13Not Applicable · OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.